Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Neuropharmacology. 2010 Dec 23;60(4):561–571. doi: 10.1016/j.neuropharm.2010.12.022

Fig. 6.

Fig. 6

Effect of CRF and selective CRF1 receptor blockade on PPI and baseline startle amplitude. Values shown are mean ± SEMs. For all groups, n = 4–9. X-axis shows Pretreatment (SC injection)/Treatment (ICV infusion). Rats received a SC injection of CP-154,526 (20.0 mg/kg) or vehicle. Two hours and forty-five minutes later, rats received an ICV infusion of 0.3 µg CRF (in 6.0 µl saline) or 6.0 µl saline. Rats were tested for PPI and startle amplitude 30 minutes after ICV infusion. (a) The average of all prepulse stimulus intensities (76, 82, 85, and 88 dB) is shown as Percent Prepulse Inhibition. ICV infusion of CRF decreased PPI (*p < 0.05 vs. Saline, main effect). CP-154,526 pretreatment did not alter the CRF-induced decrease in PPI. (b) Startle amplitude on startle stimulus alone trials that were used to calculate percent PPI. ICV infusion of CRF decreased startle amplitude (*p < 0.05 vs. Saline, main effect). CP-154,526 pretreatment did not alter the CRF-induced decrease in startle amplitude.